In light of these challenges, and to support the development of novel therapeutic strategies to exploit this important prostate cancer biological feature, we evaluated NXP800, a clinical-stage drug optimized from a hit in a phenotypic screen aimed to discover HSF1 pathway inhibitors (based on the ability to block HSP90 inhibitor-mediated HSP72 induction), which is currently being evaluated in a phase Ib clinical trial in ovarian cancer (NCT05226507; refs. 40, 43). Here, HSF1 is linked to ovarian cancer.